Edition:
United States

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Sep 21 2017

Exclusive: Africa to get state-of-art HIV drugs for $75 a year

LONDON Makers of generic AIDS drugs will start churning out millions of pills for Africa containing a state-of-the-art medicine widely used in rich countries, after securing a multi-million dollar guarantee that caps prices at just $75 per patient a year. | Video

Sep 20 2017

Sanofi tests three-in-one antibody to treat or prevent HIV

LONDON A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys.

Sep 19 2017

GlaxoSmithKline breathes easier as U.S. approves triple lung drug

LONDON U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.

Sep 18 2017

Biosimilar cancer drug threat closing in for Roche

LONDON The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 11 2017

Cancer immunotherapy proves itself in earlier-stage disease

MADRID Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body's defenses in the fight against tumors.

Sep 10 2017

Novartis posts a win, Roche a flop in skin cancer trials

ZURICH/MADRID Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group.

Sep 10 2017

After melanoma surgery, Bristol's Opdivo offers new care standard

MADRID Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.

Sep 10 2017

Bristol's drug cocktail cuts kidney cancer death risk 37 percent

MADRID A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.

Sep 10 2017

Bristol kidney cancer drug cut death risk 37 pct in key patients

MADRID, Sept 10 A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.

Sep 10 2017

Lilly takes on Pfizer, Novartis with new breast cancer drug data

NEW YORK/MADRID Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary